Overview
Daiichi Sankyo of Tokyo researches, develops, manufactures and sells pharmaceuticals; its products include the antibody-drug conjugate trastuzumab deruxtecan as well as edoxaban, prasugrel and mirogabalin.[2] Forbes records sales of US$14.1bn, up 13.9%, the third-fastest growth in this ranking after Eli Lilly and Novo Nordisk, and profit of US$1.7bn.[2] Forbes gives 2005 as the founding year and puts the market value at US$29.5bn.[2] Its product list is weighted toward oncology, alongside the anticoagulant edoxaban and the pain medicine mirogabalin.
Daiichi Sankyo strengths and limitations
Strengths
- Sales growth of 13.9%
- Lead product is an antibody-drug conjugate
- Oncology-weighted product list
Limitations
- Smaller than Takeda and Otsuka by sales
- Results translated from yen
- Profit margin about 12%
Appears in
Daiichi Sankyo peers and competitors
Companies ranked in the same lists as Daiichi Sankyo.
Johnson & Johnson- Amgen
- Astellas Pharma
Viatris- Regeneron Pharmaceuticals
- CSL
Otsuka Holdings- Teva Pharmaceutical
Merck KGaA
Gilead Sciences
Takeda Pharmaceutical
GSK plc
Is this your company?
Update the description, logo, image and link through the submission form. Editors review every change.